Neuronetics, Inc. (STIM)
NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
As of 10:05AM EDT. Market open.
| Previous close | 3.7500 |
| Open | 3.5900 |
| Bid | 2.5400 x 200 |
| Ask | 4.2100 x 200 |
| Day's range | 3.2600 - 3.5900 |
| 52-week range | 1.0300 - 5.0700 |
| Volume | |
| Avg. volume | 163,319 |
| Market cap | 101.914M |
| Beta (5Y monthly) | 2.44 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GuruFocus.com
Neuronetics Inc (STIM) Reports Q1 2024 Earnings: Revenue Surpasses Estimates, Narrowing Losses
Insight into Neuronetics' Financial Health and Strategic Advances
- Zacks
Neuronetics (STIM) Reports Q1 Loss, Tops Revenue Estimates
Neuronetics (STIM) delivered earnings and revenue surprises of 18.18% and 1.85%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
- Zacks
Neuronetics' (STIM) FDA-Cleared NeuroStar to Aid in Depression
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
© 2024 Yahoo. All rights reserved.